Introduction
Hemangiopericytoma (HPC) is a mesenchymal neoplasm constituting a minor portion of vascular tumors. 1) It was first reported in 1942 by Stout and Murray as a distinctive vascular tumor derived from Zimmerman pericytes.
2) According to the World Health Organization classification of the soft tissue and bone tumors, the term "hemangiopericytoma" refers to a wide group of tumors sharing common characteristics such as a thin-walled branching "staghorn" vascular pattern and cellular similarities of solitary fibrous tumors.
3) The term has been used roughly to describe various neoplasms that share common morphological features. Up to 15% of soft tissue neoplasms show the characteristics of HPC focally. 4) As a result, many entities have been excluded from this ambiguous category over time. HPC is now no longer considered a specific condition, but rather as a growth pattern observed in a variety of tumors. Confusion has arisen regarding this ill-defined category, leading to difficulties in predicting clinical behavior for a given neoplasm, and thus in establishing specific treatment modalities. 4) HPCs are generally benign in nature. However, some progress in a malignant course, leading to recurrence and metastasis even after radical surgery.
Atypical features, such as high mitotic rate, high cellularity, and necrotic foci, may be observed in these malignant cases. Despite the awareness of these malignant progressions, treatment criteria and accurate prediction of prognosis are not fully established.
We present a rare case of metastatic HPC of the thyroid gland with a review of characteristics and clinicopathologic features. 
Discussion
HPC is a rare tumor where the majority of patients are adults, with a female：male ratio of 3：1. 5, 6) The mean age of onset is 45 years. The most common site of occurrence is the lower extremities, followed by the retroperitoneum and the head and neck area. 3) In a study by Espat et al. 7) , extremity tumors were mostly of the axilla and thigh, whereas the head and neck area was mainly found in the meninges and the cheek. The thyroid is a very rare site of occurrence.
Cumulative data shows that it is extremely rare, with only 10 cases being reported thus far. In 1976, Enzinger and Smith 8) proposed a criterion for malignancy and they suggested that large tumor size (＞5 cm), increased mitotic rate (≥4 MF/10 HPF), high cellularity, nuclear pleomorphism, and focal hemorrhage and necrosis were predictors of a malignant course. In our case, the lesion showed an increased mitotic rate (＞10/10 HPF) and high cellularity.
The most common sites of metastasis are the lung, bones, and liver. 7, 9) Frequently, patients are present with metastases at the point of diagnosis. Previous studies reported that 11-12% of patients already had metastatic disease at the time of primary diagnosis.
The sites of metastasis in our case were the lung, bones, liver and thyroid.
Despite characteristic histopathological features and easy diagnosis, there are still no universally accepted treatment criteria or prognostic criteria. The general opinion on treatment is that complete surgical resection may be helpful in gaining a favorable outcome.
In previous studies, patients undergoing complete surgical excision showed a 100% median survival after 5 years. 7) Especially, lower local recurrence rates and higher disease-free survival were observed when lesions were associated with the extremities. 7, 9) Other treatment modalities such as radiotherapy and chemotherapy may be considered. Our patient was treated with complete surgical resection fifteen years ago, but the disease recurred twelve years later with combined multiple metastases. She was treated with several regimens of combined chemotherapy and despite effort, the disease progressed each time. The patient is currently being treated with an oral protein kinase inhibitor, and the disease is stable thus far.
The prognosis of HPC is generally good, although local recurrence and metastatic lesions arise in some patients.
3) Espat et al. 7) reported a 5-year survival rate of 80%, with a local failure rate of 4% and metastatic rate of 20%. In a study by Spitz et al. 9) , the overall 5-year survival rate was 71%, with local recurrence and metastasis occurring in 32% and 36% of patients, respectively. In a more recent, long-term follow-up study on meningeal HPCs by Shiariti et al. 10) , mean overall survival was 213 months. Local recurrence rates were 90% and 32% were affected by metastasis.
They proposed poor prognostic factors such as lowgrade tumor, incomplete excision without postoperative radiation therapy, and metastases, although the majority was not statistically significant. In thyroidal HPC, however, prognostic factors are not established due to very rare incidence.
We have presented a rare case of metastatic HPC of the thyroid gland. Although generally considered benign, the behavior of this uncommon neoplasm is still not fully understood. Frustration may arise when clinicians encounter this unpredictable tumor, especially when multiple metastases are involved as well.
Definite criteria for treatment and prognosis are necessary to ensure a disease-free interval and favorable outcome.
